Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00754312 · ClinicalTrials.gov registry record · Phase 1
A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer
A Phase 1 study, sponsored by Syndax Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00754312: Clinical Trial Phase 1 study, sponsored by Syndax Pharmaceuticals.
NCT00754312 is a Phase 1 study that was terminated before completion, run by Syndax Pharmaceuticals. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00754312, a Phase 1 study, was terminated before completion, sponsored by Syndax Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate changes in the expression of targeted biomarkers in invasive breast cancer tissue before and after SNDX-275 administration.
Interventions
- DRUG SNDX-275
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-02-28 |
| Phase | Phase 1 |
Why NCT00754312 stopped before completion
NCT00754312 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which SNDX-275 is the first listed.
NCT00754312 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00754312 about?
NCT00754312 is a clinical study titled "A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer". The primary objective of the study is to evaluate changes in the expression of targeted biomarkers in invasive breast cancer tissue before and after SNDX-275 administration.
What is the current status of trial NCT00754312?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2008-06. Estimated completion is 2009-02-28.
What interventions are being tested in trial NCT00754312?
The interventions under investigation include: SNDX-275 (DRUG).
Who is sponsoring clinical trial NCT00754312?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00754312's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia